Recurrent hepatitis C is a major cause of mortality in HIV/hepatitis C virus (HCV)-co-infected patients after orthotopic liver transplantation. We report sustained viral clearance in all four transplanted HIV/HCV-positive patients treated with pegylated interferon/ribavirin. Early therapy after HCV recurrence, tailoring treatment duration to the individual decline in HCV-RNA and the management of side effects are key factors for improved efficacy. At experienced centres interferon treatment is a valuable option for recurrent hepatitis C in HIV-positive patients.
aDepartment of Infectious Diseases and Hepatology, Medical University of Lodz, 91-347 Lodz, Poland
bDepartments of Internal Medicine I, Germany
dInstitute of Experimental Hematology and Transfusion Medicine, University of Bonn, D-53105 Bonn, Germany.
Received 17 November, 2006
Accepted 28 November, 2006